



MAYNE PHARMA LAUNCHES FIRST GENERIC METHYLPHENIDATE EXTENDED-RELEASE 10MG CAPSULES IN THE US

1 Mar 2018, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of methylphenidate extended-release (ER) capsules, 10mg, in the United States.

Methylphenidate ER capsules are a generic alternative to Ritalin LA® capsules, indicated for attention deficit hyperactivity disorder (ADHD). This launch complements the existing methylphenidate product range that includes 20mg, 30mg, 40mg and 60mg dose strengths.

Mayne Pharma's CEO Scott Richards said, "This launch reinforces Mayne Pharma's commitment to expanding its on-market portfolio. This will be the first generic alternative of the 10mg dose strength, providing more choices to patients in terms of medication affordability. Mayne Pharma directly markets more than 55 products and has a growing pipeline of more than 30 products targeting U.S. markets with QuintilesIMS sales greater than US\$5 billion."

According to IQVIA, US brand sales of methylphenidate 10mg capsules were approximately US\$20 million for the 12 months ending 31 December 2017.

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in formulation complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.

Ritalin LA® is a registered trademark of Novartis AG Corporation.